Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buspirone on Esophageal Sensitivity in Healthy Volunteers
NCT04352686Completed
- Sponsor
- UZ Leuven
- Start
- Feb 2012
- Primary completion
- Sep 2012
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial of buspirone in gastroesophageal reflux disease (GERD), sponsored by UZ Leuven. Primary endpoint: Change in sensitivity to thermal stimulation at 30 months. Started Feb 2012; status: completed.
02
Drugs
buspirone
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT04352686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04352686.